메뉴 건너뛰기




Volumn 24, Issue 7, 2010, Pages 953-964

Review: The biological basis of antipsychotic response in schizophrenia

Author keywords

Antipsychotic; Dopamine; Glutamate; Non responders; Schizophrenia; Serotonin

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; NORADRENALIN; RISPERIDONE; SEROTONIN RECEPTOR;

EID: 77953755155     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106959     Document Type: Review
Times cited : (44)

References (169)
  • 1
    • 0141788413 scopus 로고    scopus 로고
    • Prefrontal da transmission at D1 receptors and the pathology of schizophrenia
    • Abi-Dargham A., Moore H. (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9: 404-416.
    • (2003) Neuroscientist , vol.9 , pp. 404-416
    • Abi-Dargham, A.1    Moore, H.2
  • 2
    • 0034608753 scopus 로고    scopus 로고
    • Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
    • Abi-Dargham A., Rodenhiser J., Printz D., et al. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97: 8104-8109.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , pp. 8104-8109
    • Abi-Dargham, A.1    Rodenhiser, J.2    Printz, D.3
  • 3
    • 47249116664 scopus 로고    scopus 로고
    • Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder
    • Adams DH, Close S., Farmen M., Downing AM, Breier A. and Houston JP (2008) Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 23 (4). 267-274.
    • (2008) Hum Psychopharmacol , vol.23 , Issue.4 , pp. 267-274
    • Adams, D.H.1    Close, S.2    Farmen, M.3    Downing, A.M.4    Breier, A.5    Houston, J.P.6
  • 4
    • 0025140780 scopus 로고
    • Depression dexamethasone nonsuppression and negative symptoms in schizophrenia
    • Addington D., Addington J. (1990) Depression dexamethasone nonsuppression and negative symptoms in schizophrenia. Can J Psychiatry 35: 430-433.
    • (1990) Can J Psychiatry , vol.35 , pp. 430-433
    • Addington, D.1    Addington, J.2
  • 5
    • 34249085382 scopus 로고    scopus 로고
    • Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia
    • Agid O., Mamo D., Ginovart N., Vitcu I., Wilson AA, Zipursky RB, Kapur S. (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-1215.
    • (2007) Neuropsychopharmacology , vol.32 , pp. 1209-1215
    • Agid, O.1    Mamo, D.2    Ginovart, N.3    Vitcu, I.4    Wilson, A.A.5    Zipursky, R.B.6    Kapur, S.7
  • 6
    • 47649127177 scopus 로고    scopus 로고
    • Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting
    • Alenius M., Wadelius M., Dahl ML, Hartvig P., Lindstrom L. and Hammarlund-Udenaes M. (2008) Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 42 (11). 884-893.
    • (2008) J Psychiatr Res , vol.42 , Issue.11 , pp. 884-893
    • Alenius, M.1    Wadelius, M.2    Dahl, M.L.3    Hartvig, P.4    Lindstrom, L.5    Hammarlund-Udenaes, M.6
  • 7
    • 0025325739 scopus 로고
    • Relationships between clinical effects and monoamine metabolites and amino acids in sulpiridetreated schizophrenic patients
    • Berl
    • Alfredsson G., Wiesel FA (1990) Relationships between clinical effects and monoamine metabolites and amino acids in sulpiridetreated schizophrenic patients. Psychopharmacology (Berl) 101: 324-331.
    • (1990) Psychopharmacology , vol.101 , pp. 324-331
    • Alfredsson, G.1    Wiesel, F.A.2
  • 9
    • 0028917102 scopus 로고
    • Assessment of the central dopaminergic index of plasma HVA in schizophrenia
    • Amin F., Davidson M., Kahn RS, et al. (1995) Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 21: 53-66.
    • (1995) Schizophr Bull , vol.21 , pp. 53-66
    • Amin, F.1    Davidson, M.2    Kahn, R.S.3
  • 10
    • 0042882523 scopus 로고    scopus 로고
    • The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    • Arango C., Breier A., McMahon R., Carpenter WT, Jr, Buchanan RW (2003) The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry 160: 1421-1427.
    • (2003) Am J Psychiatry , vol.160 , pp. 1421-1427
    • Arango, C.1    Breier, A.2    McMahon, R.3    Buchanan, R.W.4
  • 11
    • 0029100429 scopus 로고
    • Association between clozapine response and allelic variation in 5-HT2A receptor gene
    • Arranz M., Collier D., Sodhi M., et al. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346 (8970). 281-282.
    • (1995) Lancet , vol.346 , Issue.8970 , pp. 281-282
    • Arranz, M.1    Collier, D.2    Sodhi, M.3
  • 13
    • 0030592571 scopus 로고    scopus 로고
    • Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
    • Arranz MJ, Collier DA, Munro J., et al. (1996) Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 217: 177-178.
    • (1996) Neurosci Lett , vol.217 , pp. 177-178
    • Arranz, M.J.1    Collier, D.A.2    Munro, J.3
  • 14
    • 34547469943 scopus 로고    scopus 로고
    • Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research
    • Arranz MJ, de Leon J. (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12: 707-747.
    • (2007) Mol Psychiatry , vol.12 , pp. 707-747
    • Arranz, M.J.1    De Leon, J.2
  • 15
    • 0032217288 scopus 로고    scopus 로고
    • Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
    • Arranz MJ, Li T., Munro J., et al. (1998) Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 8 (6). 481-484. (Pubitemid 29043380)
    • (1998) Pharmacogenetics , vol.8 , Issue.6 , pp. 481-484
    • Arranz, M.J.1    Li, T.2    Munro, J.3    Liu, X.4    Murray, R.5    Collier, D.A.6    Kerwin, R.W.7
  • 17
    • 0021235828 scopus 로고
    • Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test
    • Banki CM, Arato M., Rihmer Z. (1984) Neuroendocrine differences among subtypes of schizophrenic disorder? An investigation with the dexamethasone suppression test. Neuropsychobiology 11: 174-177.
    • (1984) Neuropsychobiology , vol.11 , pp. 174-177
    • Banki, C.M.1    Arato, M.2    Rihmer, Z.3
  • 18
    • 58849142941 scopus 로고    scopus 로고
    • (2009) Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients
    • Barlas IO, Cetin M., Erdal ME, et al. (2009) Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet 150B (1). 56-60.
    • Am J Med Genet B Neuropsychiatr Genet , vol.150 , Issue.1 , pp. 56-60
    • Barlas, I.O.1    Cetin, M.2    Erdal, M.E.3
  • 19
    • 0242490991 scopus 로고    scopus 로고
    • Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients
    • Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI (2003) Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry 11: 648-657.
    • (2003) Am J Geriatr Psychiatry , vol.11 , pp. 648-657
    • Bartels, S.J.1    Clark, R.E.2    Peacock, W.J.3    Dums, A.R.4    Pratt, S.I.5
  • 20
    • 4744376592 scopus 로고    scopus 로고
    • Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia
    • Bertolino A., Caforio G., Blasi G., et al. (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161 (10). 1798-1805.
    • (2004) Am J Psychiatry , vol.161 , Issue.10 , pp. 1798-1805
    • Bertolino, A.1    Caforio, G.2    Blasi, G.3
  • 21
    • 34548160606 scopus 로고    scopus 로고
    • COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia
    • Bertolino A., Caforio G., Blasi G., et al. (2007) COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 95: 253-255.
    • (2007) Schizophr Res , vol.95 , pp. 253-255
    • Bertolino, A.1    Caforio, G.2    Blasi, G.3
  • 22
    • 0012820694 scopus 로고    scopus 로고
    • Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response
    • Birkett JT, Arranz MJ, Munro J., Osbourn S., Kerwin RW, Collier DA (2000) Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 11: 2017-2020.
    • (2000) Neuroreport , vol.11 , pp. 2017-2020
    • Birkett, J.T.1    Arranz, M.J.2    Munro, J.3    Osbourn, S.4    Kerwin, R.W.5    Collier, D.A.6
  • 23
    • 23444450578 scopus 로고    scopus 로고
    • Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
    • Bishop JR, Ellingrod VL, Moline J., Miller D. (2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 77: 253-260.
    • (2005) Schizophr Res , vol.77 , pp. 253-260
    • Bishop, J.R.1    Ellingrod, V.L.2    Moline, J.3    Miller, D.4
  • 24
    • 0033956560 scopus 로고    scopus 로고
    • No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response
    • Bolonna AA, Arranz MJ, Munro J., et al. (2000) No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 280: 65-68.
    • (2000) Neurosci Lett , vol.280 , pp. 65-68
    • Bolonna, A.A.1    Arranz, M.J.2    Munro, J.3
  • 25
    • 0021241811 scopus 로고
    • Plasma catecholamine metabolites and early response to haloperidol
    • Bowers MB, Jr, Swigar ME, Jatlow PI, Goicoechea N. (1984) Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45: 248-251.
    • (1984) J Clin Psychiatry , vol.45 , pp. 248-251
    • Swigar, M.E.1    Jatlow, P.I.2    Goicoechea, N.3
  • 26
    • 0024512548 scopus 로고
    • Plasma catecholamine metabolites and treatment response at neuroleptic steady state
    • Bowers MB, Jr, Swigar ME, Jatlow PI, Hoffman FJ (1989) Plasma catecholamine metabolites and treatment response at neuroleptic steady state. Biol Psychiatry 25: 734-738.
    • (1989) Biol Psychiatry , vol.25 , pp. 734-738
    • Swigar, M.E.1    Jatlow, P.I.2    Hoffman, F.J.3
  • 27
    • 0030776916 scopus 로고    scopus 로고
    • Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: A within-subject comparison with haloperidol
    • Brown AS, Gewirtz G., Harkavy-Friedman J., et al. (1997) Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 17: 317-325.
    • (1997) Neuropsychopharmacology , vol.17 , pp. 317-325
    • Brown, A.S.1    Gewirtz, G.2    Harkavy-Friedman, J.3
  • 28
    • 0028785179 scopus 로고
    • New insights into the biology of schizophrenia through the mechanism of action of clozapine
    • Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177-213.
    • (1995) Neuropsychopharmacology , vol.13 , pp. 177-213
    • Brunello, N.1    Masotto, C.2    Steardo, L.3    Markstein, R.4    Racagni, G.5
  • 29
    • 0031746826 scopus 로고    scopus 로고
    • Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
    • Buchanan RW, Breier A., Kirkpatrick B., Ball P., Carpenter WT, Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155: 751-760.
    • (1998) Am J Psychiatry , vol.155 , pp. 751-760
    • Buchanan, R.W.1    Breier, A.2    Kirkpatrick, B.3    Ball, P.4
  • 30
    • 0026467217 scopus 로고
    • Striatal metabolic rate and clinical response to neuroleptics in schizophrenia
    • Buchsbaum MS, Potkin SG, Siegel BV, Jr, et al. (1992) Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 49 (12). 966-974.
    • (1992) Arch Gen Psychiatry , vol.49 , Issue.12 , pp. 966-974
    • Buchsbaum, M.S.1    Potkin, S.G.2
  • 31
    • 0019435794 scopus 로고
    • A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility
    • Carroll BJ, Feinberg M., Greden JF, et al. (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38: 15-22.
    • (1981) Arch Gen Psychiatry , vol.38 , pp. 15-22
    • Carroll, B.J.1    Feinberg, M.2    Greden, J.F.3
  • 32
    • 33751001329 scopus 로고    scopus 로고
    • Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response
    • Catafau AM, Corripio I., Perez V., Martin JC, Schotte A., Carrio I., Alvarez E. (2006) Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res 148: 175-183.
    • (2006) Psychiatry Res , vol.148 , pp. 175-183
    • Catafau, A.M.1    Corripio, I.2    Perez, V.3    Martin, J.C.4    Schotte, A.5    Carrio, I.6    Alvarez, E.7
  • 34
    • 0036016287 scopus 로고    scopus 로고
    • Biological markers and possibilities for predicting therapeutic results in schizophrenia: A methodological contribution
    • Ceskova E., Drybcak P., Lorenc M. (2002) Biological markers and possibilities for predicting therapeutic results in schizophrenia: a methodological contribution. Prog Neuropsychopharmacol Biol Psychiatry 26: 683-691.
    • (2002) Prog Neuropsychopharmacol Biol Psychiatry , vol.26 , pp. 683-691
    • Ceskova, E.1    Drybcak, P.2    Lorenc, M.3
  • 35
    • 0025275157 scopus 로고
    • Plasma catecholamine metabolites in schizophrenics: Evidence for the two-subtype concept
    • Chang WH, Chen TY, Lin SK, et al. (1990) Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept. Biol Psychiatry 27: 510-518.
    • (1990) Biol Psychiatry , vol.27 , pp. 510-518
    • Chang, W.H.1    Chen, T.Y.2    Lin, S.K.3
  • 36
    • 0038009306 scopus 로고    scopus 로고
    • Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese
    • Chiu HJ, Wang YC, Liou YJ, Lai IC, Chen JY (2003) Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology 47 (4). 178-181.
    • (2003) Neuropsychobiology , vol.47 , Issue.4 , pp. 178-181
    • Chiu, H.J.1    Wang, Y.C.2    Liou, Y.J.3    Lai, I.C.4    Chen, J.Y.5
  • 37
    • 0032587535 scopus 로고    scopus 로고
    • Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs
    • Berl
    • Cohen BM, Ennulat DJ, Centorrino F., et al. (1999) Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 141 (1). 6-10.
    • (1999) Psychopharmacology , vol.141 , Issue.1 , pp. 6-10
    • Cohen, B.M.1    Ennulat, D.J.2    Centorrino, F.3
  • 39
    • 33748864195 scopus 로고    scopus 로고
    • Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia
    • Cordeiro Q., Miguita K., Miracca E., Elkis H. and Vallada H. (2006) Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia. Sao Paulo Med J 124 (3). 165-167.
    • (2006) Sao Paulo Med J , vol.124 , Issue.3 , pp. 165-167
    • Cordeiro, Q.1    Miguita, K.2    Miracca, E.3    Elkis, H.4    Vallada, H.5
  • 40
    • 10944267670 scopus 로고    scopus 로고
    • Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: A 123I-IBZM study with ziprasidone and haloperidol
    • Corripio I., Catafau AM, Perez V., et al. (2005) Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 29: 91-96.
    • (2005) Prog Neuropsychopharmacol Biol Psychiatry , vol.29 , pp. 91-96
    • Corripio, I.1    Catafau, A.M.2    Perez, V.3
  • 41
    • 0017255979 scopus 로고
    • Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
    • Creese I., Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483.
    • (1976) Science , vol.192 , pp. 481-483
    • Creese, I.1    Burt, D.R.2    Snyder, S.H.3
  • 42
    • 0018899460 scopus 로고
    • Molecular pathology of schizophrenia: More than one disease process
    • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process ? Br Med J 280 (6207). 66-68.
    • (1980) Br Med J , vol.280 , Issue.6207 , pp. 66-68
    • Crow, T.J.1
  • 43
    • 0029037226 scopus 로고
    • Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement
    • Curtis VA, Wright P., Reveley A., Kerwin R., Lucey JV (1995) Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiatry 166: 642-646.
    • (1995) Br J Psychiatry , vol.166 , pp. 642-646
    • Curtis, V.A.1    Wright, P.2    Reveley, A.3    Kerwin, R.4    Lucey, J.V.5
  • 44
    • 0027461574 scopus 로고
    • Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia
    • Davidson M., Kahn RS, Stern RG, et al. (1993) Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 46 (2). 151-163.
    • (1993) Psychiatry Res , vol.46 , Issue.2 , pp. 151-163
    • Davidson, M.1    Kahn, R.S.2    Stern, R.G.3
  • 46
    • 0035113905 scopus 로고    scopus 로고
    • A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications
    • Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. (2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24 (1). 43-49.
    • (2001) Clin Neuropharmacol , vol.24 , Issue.1 , pp. 43-49
    • Deutsch, S.I.1    Rosse, R.B.2    Schwartz, B.L.3    Mastropaolo, J.4
  • 47
    • 0019946065 scopus 로고
    • Abnormal dexamethasone suppression test results in chronic schizophrenic patients
    • Dewan MJ, Pandurangi AK, Boucher ML, Levy BF, Major LF (1982) Abnormal dexamethasone suppression test results in chronic schizophrenic patients. Am J Psychiatry 139 (11). 1501-1503.
    • (1982) Am J Psychiatry , vol.139 , Issue.11 , pp. 1501-1503
    • Dewan, M.J.1    Pandurangi, A.K.2    Boucher, M.L.3    Levy, B.F.4    Major, L.F.5
  • 48
    • 0027441907 scopus 로고
    • Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics
    • Duncan E., Wolkin A., Angrist B., et al. (1993) Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 34 (8). 523-528.
    • (1993) Biol Psychiatry , vol.34 , Issue.8 , pp. 523-528
    • Duncan, E.1    Wolkin, A.2    Angrist, B.3
  • 49
    • 0026503249 scopus 로고
    • PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients
    • Farde L., Nordstrom AL (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl 17). 30-33.
    • (1992) Br J Psychiatry Suppl , vol.17 , pp. 30-33
    • Farde, L.1    Nordstrom, A.L.2
  • 50
    • 36849051883 scopus 로고    scopus 로고
    • No association between the DRD3 Ser9Gly polymorphism and schizophrenia
    • Fathalli F., Rouleau GA, Xiong L., et al. (2008) No association between the DRD3 Ser9Gly polymorphism and schizophrenia. Schizophr Res 98 (1-3). 98-104.
    • (2008) Schizophr Res , vol.98 , Issue.1-3 , pp. 98-104
    • Fathalli, F.1    Rouleau, G.A.2    Xiong, L.3
  • 51
    • 0026970230 scopus 로고
    • The relationship of structural brain imaging parameters to antipsychotic treatment response: A review
    • Friedman L., Lys C., Schulz SC (1992) The relationship of structural brain imaging parameters to antipsychotic treatment response: a review. J Psychiatry Neurosci 17 (2). 42-54.
    • (1992) J Psychiatry Neurosci , vol.17 , Issue.2 , pp. 42-54
    • Friedman, L.1    Lys, C.2    Schulz, S.C.3
  • 53
    • 0037087350 scopus 로고    scopus 로고
    • Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine
    • Goff DC, Hennen J., Lyoo IK, et al. (2002) Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51 (6). 493-497.
    • (2002) Biol Psychiatry , vol.51 , Issue.6 , pp. 493-497
    • Goff, D.C.1    Hennen, J.2    Lyoo, I.K.3
  • 54
    • 0027327459 scopus 로고
    • Haloperidol response and plasma catecholamines and their metabolites
    • Green AI, Alam MY, Boshes RA, et al. (1993 a) Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 10 (1). 33-37.
    • (1993) Schizophr Res , vol.10 , Issue.1 , pp. 33-37
    • Green, A.I.1    Alam, M.Y.2    Boshes, R.A.3
  • 55
    • 0027411804 scopus 로고
    • Clozapine response and plasma catecholamines and their metabolites
    • Green AI, Alam MY, Sobieraj JT, et al. (1993 b) Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 46 (2). 139-149.
    • (1993) Psychiatry Res , vol.46 , Issue.2 , pp. 139-149
    • Green, A.I.1    Alam, M.Y.2    Sobieraj, J.T.3
  • 56
    • 0038388945 scopus 로고    scopus 로고
    • Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo
    • Grunder G., Vernaleken I., Muller MJ, et al. (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (4). 787-794.
    • (2003) Neuropsychopharmacology , vol.28 , Issue.4 , pp. 787-794
    • Grunder, G.1    Vernaleken, I.2    Muller, M.J.3
  • 57
    • 0036843194 scopus 로고    scopus 로고
    • Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response
    • Gutierrez B., Arranz MJ, Huezo-Diaz P., et al. (2002) Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 58 (1). 93-97.
    • (2002) Schizophr Res , vol.58 , Issue.1 , pp. 93-97
    • Gutierrez, B.1    Arranz, M.J.2    Huezo-Diaz, P.3
  • 58
    • 33846907203 scopus 로고    scopus 로고
    • Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms
    • Guzey C., Scordo MG, Spina E., Landsem VM and Spigset O. (2007) Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 63 (3). 233-241.
    • (2007) Eur J Clin Pharmacol , vol.63 , Issue.3 , pp. 233-241
    • Guzey, C.1    Scordo, M.G.2    Spina, E.3    Landsem, V.M.4    Spigset, O.5
  • 59
    • 0035703938 scopus 로고    scopus 로고
    • Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia
    • Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ (2001) Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 11 (4). 219-222.
    • (2001) Psychiatr Genet , vol.11 , Issue.4 , pp. 219-222
    • Hong, C.J.1    Yu, Y.W.2    Lin, C.H.3    Cheng, C.Y.4    Tsai, S.J.5
  • 60
    • 26644464161 scopus 로고    scopus 로고
    • Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations
    • Berl
    • Hwang R., Shinkai T., De Luca V., et al. (2005) Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 181 (1). 179-187.
    • (2005) Psychopharmacology , vol.181 , Issue.1 , pp. 179-187
    • Hwang, R.1    Shinkai, T.2    De Luca, V.3
  • 61
    • 34548854787 scopus 로고    scopus 로고
    • Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response
    • Hwang R., Shinkai T., De Luca V., et al. (2007) Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 21 (7). 718-727.
    • (2007) J Psychopharmacol , vol.21 , Issue.7 , pp. 718-727
    • Hwang, R.1    Shinkai, T.2    De Luca, V.3
  • 62
    • 17544400122 scopus 로고    scopus 로고
    • Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
    • Hwu HG, Hong CJ, Lee YL, Lee PC and Lee SF (1998) Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 44 (6). 483-487.
    • (1998) Biol Psychiatry , vol.44 , Issue.6 , pp. 483-487
    • Hwu, H.G.1    Hong, C.J.2    Lee, Y.L.3    Lee, P.C.4    Lee, S.F.5
  • 63
    • 0242586089 scopus 로고    scopus 로고
    • Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics
    • Illi A., Kampman O., Anttila S., et al. (2003) Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 13 (3). 147-151.
    • (2003) Eur Neuropsychopharmacol , vol.13 , Issue.3 , pp. 147-151
    • Illi, A.1    Kampman, O.2    Anttila, S.3
  • 64
    • 34250635128 scopus 로고    scopus 로고
    • Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia
    • Illi A., Kampman O., Hanninen K., et al. (2007) Catechol-O- methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum Psychopharmacol 22 (4). 211-215.
    • (2007) Hum Psychopharmacol , vol.22 , Issue.4 , pp. 211-215
    • Illi, A.1    Kampman, O.2    Hanninen, K.3
  • 65
    • 0042322722 scopus 로고    scopus 로고
    • Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia
    • Inada T., Nakamura A. and Iijima Y. (2003) Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet B Neuropsychiatr Genet 120B (1). 35-39.
    • (2003) Am J Med Genet B Neuropsychiatr Genet , vol.120 , Issue.1 , pp. 35-39
    • Inada, T.1    Nakamura, A.2    Iijima, Y.3
  • 67
    • 0001278077 scopus 로고    scopus 로고
    • Management of negative symptoms of schizophrenia
    • Javitt DC (2001) Management of negative symptoms of schizophrenia. Curr Psychiatry Rep 3 (5). 413-417.
    • (2001) Curr Psychiatry Rep , vol.3 , Issue.5 , pp. 413-417
    • Javitt, D.C.1
  • 68
    • 33646832723 scopus 로고    scopus 로고
    • Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients
    • Javitt DC (2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19 (2). 151-157.
    • (2006) Curr Opin Psychiatry , vol.19 , Issue.2 , pp. 151-157
    • Javitt, D.C.1
  • 69
    • 0031745928 scopus 로고    scopus 로고
    • Neuroendocrine evidence that clozapines serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms
    • Jones H., Curtis VA, Wright P., Lucey JV (1998) Neuroendocrine evidence that clozapines serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Am J Psychiatry 155 (6). 838-840.
    • (1998) Am J Psychiatry , vol.155 , Issue.6 , pp. 838-840
    • Jones, H.1    Curtis, V.A.2    Wright, P.3    Lucey, J.V.4
  • 70
    • 0037114888 scopus 로고    scopus 로고
    • D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients
    • Jones H., Curtis VA, Wright P., Pilowsky LS, Lucey JV (2002) D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients. Psychiatry Res 113 (1-2). 41-47.
    • (2002) Psychiatry Res , vol.113 , Issue.1-2 , pp. 41-47
    • Jones, H.1    Curtis, V.A.2    Wright, P.3    Pilowsky, L.S.4    Lucey, J.V.5
  • 71
    • 0027268149 scopus 로고
    • Serotonin function and treatment response to clozapine in schizophrenic patients
    • Kahn RS, Davidson M., Siever L., Gabriel S., Apter S., Davis KL (1993) Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry 150 (9). 1337-1342.
    • (1993) Am J Psychiatry , vol.150 , Issue.9 , pp. 1337-1342
    • Kahn, R.S.1    Davidson, M.2    Siever, L.3    Gabriel, S.4    Apter, S.5    Davis, K.L.6
  • 72
    • 0033945594 scopus 로고    scopus 로고
    • Dopamine D4 receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia
    • Kaiser R., Konneker M., Henneken M., et al. (2000) Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 5 (4). 418-424.
    • (2000) Mol Psychiatry , vol.5 , Issue.4 , pp. 418-424
    • Kaiser, R.1    Konneker, M.2    Henneken, M.3
  • 73
    • 0036366101 scopus 로고    scopus 로고
    • Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia
    • Kaiser R., Tremblay PB, Klufmoller F., Roots I. and Brockmoller J. (2002) Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7 (7). 695-705.
    • (2002) Mol Psychiatry , vol.7 , Issue.7 , pp. 695-705
    • Kaiser, R.1    Tremblay, P.B.2    Klufmoller, F.3    Roots, I.4    Brockmoller, J.5
  • 74
    • 0023812652 scopus 로고
    • Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
    • Kane J., Honigfeld G., Singer J., Meltzer H. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (9). 789-796.
    • (1988) Arch Gen Psychiatry , vol.45 , Issue.9 , pp. 789-796
    • Kane, J.1    Honigfeld, G.2    Singer, J.3    Meltzer, H.4
  • 75
    • 33644876274 scopus 로고    scopus 로고
    • Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia
    • Kaneda Y., Kawamura I., Ohmori T. (2005) Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia. Clin Neuropharmacol 28 (6). 262-264.
    • (2005) Clin Neuropharmacol , vol.28 , Issue.6 , pp. 262-264
    • Kaneda, Y.1    Kawamura, I.2    Ohmori, T.3
  • 76
    • 0035660215 scopus 로고    scopus 로고
    • Dopamine D(2) receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient
    • Kapur S., Remington G. (2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50 (11). 873-883.
    • (2001) Biol Psychiatry , vol.50 , Issue.11 , pp. 873-883
    • Kapur, S.1    Remington, G.2
  • 77
    • 0020327692 scopus 로고
    • Influence of dopamine agonists on plasma and brain levels of homovanillic acid
    • Kendler KS, Heninger GR, Roth RH (1982) Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci 30 (24). 2063-2069.
    • (1982) Life Sci , vol.30 , Issue.24 , pp. 2063-2069
    • Kendler, K.S.1    Heninger, G.R.2    Roth, R.H.3
  • 78
    • 38649086421 scopus 로고    scopus 로고
    • Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting
    • Kim B., Choi EY, Kim CY, Song K., Joo YH (2008) Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 23 (1). 61-67.
    • (2008) Hum Psychopharmacol , vol.23 , Issue.1 , pp. 61-67
    • Kim, B.1    Choi, E.Y.2    Kim, C.Y.3    Song, K.4    Joo, Y.H.5
  • 79
    • 0030940989 scopus 로고    scopus 로고
    • Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects
    • Kohn Y., Ebstein RP, Heresco-Levy U., et al. (1997) Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 7 (1). 39-43.
    • (1997) Eur Neuropsychopharmacol , vol.7 , Issue.1 , pp. 39-43
    • Kohn, Y.1    Ebstein, R.P.2    Heresco-Levy, U.3
  • 80
    • 0028121087 scopus 로고
    • Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response
    • Koreen AR, Lieberman J., Alvir J., et al. (1994) Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 51 (2). 132-138.
    • (1994) Arch Gen Psychiatry , vol.51 , Issue.2 , pp. 132-138
    • Koreen, A.R.1    Lieberman, J.2    Alvir, J.3
  • 81
    • 0036713871 scopus 로고    scopus 로고
    • Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene
    • Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH (2002) Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 159 (9). 1593-1595.
    • (2002) Am J Psychiatry , vol.159 , Issue.9 , pp. 1593-1595
    • Lane, H.Y.1    Chang, Y.C.2    Chiu, C.C.3    Chen, M.L.4    Hsieh, M.H.5    Chang, W.H.6
  • 83
    • 0029555412 scopus 로고
    • Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia
    • Lawrie SM, Ingle GT, Santosh CG, et al. (1995) Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia. Br J Psychiatry 167 (2). 202-210.
    • (1995) Br J Psychiatry , vol.167 , Issue.2 , pp. 202-210
    • Lawrie, S.M.1    Ingle, G.T.2    Santosh, C.G.3
  • 84
    • 40449123512 scopus 로고    scopus 로고
    • CATIE and CUtLASS: Can we handle the truth
    • Lewis S., Lieberman J. (2008) CATIE and CUtLASS: can we handle the truth ? Br J Psychiatry 192 (3). 161-163.
    • (2008) Br J Psychiatry , vol.192 , Issue.3 , pp. 161-163
    • Lewis, S.1    Lieberman, J.2
  • 85
    • 0032821589 scopus 로고    scopus 로고
    • Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective
    • Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46 (6). 729-739.
    • (1999) Biol Psychiatry , vol.46 , Issue.6 , pp. 729-739
    • Lieberman, J.A.1
  • 87
    • 0002964661 scopus 로고    scopus 로고
    • No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
    • Lin CH, Tsai SJ, Yu YW, et al. (1999) No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 10 (1). 57-60.
    • (1999) Neuroreport , vol.10 , Issue.1 , pp. 57-60
    • Lin, C.H.1    Tsai, S.J.2    Yu, Y.W.3
  • 88
    • 0029949349 scopus 로고    scopus 로고
    • Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine
    • Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168 (5). 571-579.
    • (1996) Br J Psychiatry , vol.168 , Issue.5 , pp. 571-579
    • Litman, R.E.1    Su, T.P.2    Potter, W.Z.3    Hong, W.W.4    Pickar, D.5
  • 89
    • 0029790119 scopus 로고    scopus 로고
    • Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine
    • Malhotra AK, Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. (1996 a) Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 153 (8). 1092-1094.
    • (1996) Am J Psychiatry , vol.153 , Issue.8 , pp. 1092-1094
    • Malhotra, A.K.1    Goldman, D.2    Ozaki, N.3    Breier, A.4    Buchanan, R.5    Pickar, D.6
  • 90
    • 0029658220 scopus 로고    scopus 로고
    • Clozapine response and the 5HT2C Cys23Ser polymorphism
    • Malhotra AK, Goldman D., Ozaki N., et al. (1996 b) Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport 7 (13). 2100-2102.
    • (1996) Neuroreport , vol.7 , Issue.13 , pp. 2100-2102
    • Malhotra, A.K.1    Goldman, D.2    Ozaki, N.3
  • 91
    • 0031594223 scopus 로고    scopus 로고
    • The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response
    • Malhotra AK, Goldman D., Buchanan RW, et al. (1998) The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 3 (1). 72-75.
    • (1998) Mol Psychiatry , vol.3 , Issue.1 , pp. 72-75
    • Malhotra, A.K.1    Goldman, D.2    Buchanan, R.W.3
  • 92
    • 0031861847 scopus 로고    scopus 로고
    • Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
    • Masellis M., Basile V., Meltzer HY, et al. (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19 (2). 123-132.
    • (1998) Neuropsychopharmacology , vol.19 , Issue.2 , pp. 123-132
    • Masellis, M.1    Basile, V.2    Meltzer, H.Y.3
  • 93
    • 0035863032 scopus 로고    scopus 로고
    • Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia
    • Masellis M., Basile VS, Meltzer HY, et al. (2001) Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 47 (1). 49-58.
    • (2001) Schizophr Res , vol.47 , Issue.1 , pp. 49-58
    • Masellis, M.1    Basile, V.S.2    Meltzer, H.Y.3
  • 94
    • 0028862241 scopus 로고
    • Genetic variation of 5-HT2A receptor and response to clozapine
    • Masellis M., Paterson AD, Badri F., et al. (1995) Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 346 (8982). 1108.
    • (1995) Lancet , vol.346 , Issue.8982 , pp. 1108
    • Masellis, M.1    Paterson, A.D.2    Badri, F.3
  • 95
    • 0028123460 scopus 로고
    • Prediction of response to haloperidol in schizophrenia: Neuroendocrine, neuromorphological and clinical variables
    • Mauri MC, Vita A., Giobbio GM, et al. (1994) Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol 9 (1). 3-7.
    • (1994) Int Clin Psychopharmacol , vol.9 , Issue.1 , pp. 3-7
    • Mauri, M.C.1    Vita, A.2    Giobbio, G.M.3
  • 96
    • 0026046111 scopus 로고
    • Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis
    • Mazure CM, Nelson JC, Jatlow PI, Bowers MB (1991) Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 30 (5). 475-482.
    • (1991) Biol Psychiatry , vol.30 , Issue.5 , pp. 475-482
    • Mazure, C.M.1    Nelson, J.C.2    Jatlow, P.I.3    Bowers, M.B.4
  • 97
    • 0021327419 scopus 로고
    • Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms
    • Meltzer HY, Kolakowska T., Fang VS, et al. (1984) Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Arch Gen Psychiatry 41 (5). 512-519.
    • (1984) Arch Gen Psychiatry , vol.41 , Issue.5 , pp. 512-519
    • Meltzer, H.Y.1    Kolakowska, T.2    Fang, V.S.3
  • 98
    • 0032570653 scopus 로고    scopus 로고
    • Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia
    • Mohr P., Horacek J., Motlova L., Libiger J., Czobor P. (1998) Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophr Res 30 (1). 91-99.
    • (1998) Schizophr Res , vol.30 , Issue.1 , pp. 91-99
    • Mohr, P.1    Horacek, J.2    Motlova, L.3    Libiger, J.4    Czobor, P.5
  • 99
    • 34548185207 scopus 로고    scopus 로고
    • Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment
    • Molero P., Ortuno F., Zalacain M. and Patino-Garcia A. (2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7 (6). 418-426.
    • (2007) Pharmacogenomics J , vol.7 , Issue.6 , pp. 418-426
    • Molero, P.1    Ortuno, F.2    Zalacain, M.3    Patino-Garcia, A.4
  • 101
    • 10744222659 scopus 로고    scopus 로고
    • Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia
    • Molina V., Reig S., Pascau J., et al. (2003 a) Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Res 124 (3). 163-175.
    • (2003) Psychiatry Res , vol.124 , Issue.3 , pp. 163-175
    • Molina, V.1    Reig, S.2    Pascau, J.3
  • 103
    • 3142621070 scopus 로고    scopus 로고
    • Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia
    • Molina V., Sanz J., Benito C., Palomo T. (2004) Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia. Int Clin Psychopharmacol 19 (4). 221-228.
    • (2004) Int Clin Psychopharmacol , vol.19 , Issue.4 , pp. 221-228
    • Molina, V.1    Sanz, J.2    Benito, C.3    Palomo, T.4
  • 104
    • 42949126347 scopus 로고    scopus 로고
    • Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients
    • Molina V., Tamayo P., Montes C., et al. (2008) Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 32 (4). 948-954.
    • (2008) Prog Neuropsychopharmacol Biol Psychiatry , vol.32 , Issue.4 , pp. 948-954
    • Molina, V.1    Tamayo, P.2    Montes, C.3
  • 105
    • 0021359017 scopus 로고
    • The dexamethasone suppression test in residual schizophrenia with depression
    • Munro JG, Hardiker TM, Leonard DP (1984) The dexamethasone suppression test in residual schizophrenia with depression. Am J Psychiatry 141 (2). 250-252.
    • (1984) Am J Psychiatry , vol.141 , Issue.2 , pp. 250-252
    • Munro, J.G.1    Hardiker, T.M.2    Leonard, D.P.3
  • 106
    • 0030935816 scopus 로고    scopus 로고
    • First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment
    • Nagaoka S., Iwamoto N., Arai H. (1997) First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry 41 (8). 857-864.
    • (1997) Biol Psychiatry , vol.41 , Issue.8 , pp. 857-864
    • Nagaoka, S.1    Iwamoto, N.2    Arai, H.3
  • 107
    • 2642572803 scopus 로고    scopus 로고
    • Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
    • Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23 (6). 540-545.
    • (2004) Hum Mutat , vol.23 , Issue.6 , pp. 540-545
    • Neville, M.J.1    Johnstone, E.C.2    Walton, R.T.3
  • 108
    • 33744499186 scopus 로고    scopus 로고
    • Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics
    • Nolan KA, Czobor P., Citrome LL, et al. (2006) Catechol-O- methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. J Clin Psychopharmacol 26 (3). 338-340.
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.3 , pp. 338-340
    • Nolan, K.A.1    Czobor, P.2    Citrome, L.L.3
  • 109
    • 0029151653 scopus 로고
    • Genetic variation of the 5-HT2A receptor and response to clozapine
    • Nothen MM, Rietschel M., Erdmann J., et al. (1995) Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 346 (8979). 908-909.
    • (1995) Lancet , vol.346 , Issue.8979 , pp. 908-909
    • Nothen, M.M.1    Rietschel, M.2    Erdmann, J.3
  • 110
    • 0032538921 scopus 로고    scopus 로고
    • Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia
    • Ohara K., Nagai M., Tani K., Nakamura Y., Ino A. and Ohara K. (1998) Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res 81 (2). 117-123.
    • (1998) Psychiatry Res , vol.81 , Issue.2 , pp. 117-123
    • Ohara, K.1    Nagai, M.2    Tani, K.3    Nakamura, Y.4    Ino, A.5    Ohara, K.6
  • 111
    • 0029869847 scopus 로고    scopus 로고
    • Drug strategies and treatment-resistant schizophrenia
    • Pantelis C., Barnes TR (1996) Drug strategies and treatment-resistant schizophrenia. Aust N Z J Psychiatry 30 (1). 20-37.
    • (1996) Aust N Z J Psychiatry , vol.30 , Issue.1 , pp. 20-37
    • Pantelis, C.1    Barnes, T.R.2
  • 112
    • 34948858402 scopus 로고    scopus 로고
    • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial
    • Patil ST, Zhang L., Martenyi F., et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13 (9). 1102-1107.
    • (2007) Nat Med , vol.13 , Issue.9 , pp. 1102-1107
    • Patil, S.T.1    Zhang, L.2    Martenyi, F.3
  • 113
    • 26444464824 scopus 로고    scopus 로고
    • Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis
    • Perkins DO, Gu H., Boteva K., Lieberman JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162 (10). 1785-1804.
    • (2005) Am J Psychiatry , vol.162 , Issue.10 , pp. 1785-1804
    • Perkins, D.O.1    Gu, H.2    Boteva, K.3    Lieberman, J.A.4
  • 115
    • 0022620254 scopus 로고
    • Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment
    • Pickar D., Labarca R., Doran AR, et al. (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43 (7). 669-676.
    • (1986) Arch Gen Psychiatry , vol.43 , Issue.7 , pp. 669-676
    • Pickar, D.1    Labarca, R.2    Doran, A.R.3
  • 116
    • 0021254347 scopus 로고
    • Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
    • Pickar D., Labarca R., Linnoila M., et al. (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225 (4665). 954-957.
    • (1984) Science , vol.225 , Issue.4665 , pp. 954-957
    • Pickar, D.1    Labarca, R.2    Linnoila, M.3
  • 117
    • 31544442970 scopus 로고    scopus 로고
    • First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
    • Pilowsky LS, Bressan RA, Stone JM, et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11 (2). 118-119.
    • (2006) Mol Psychiatry , vol.11 , Issue.2 , pp. 118-119
    • Pilowsky, L.S.1    Bressan, R.A.2    Stone, J.M.3
  • 118
    • 0026643193 scopus 로고
    • Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
    • Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340 (8813). 199-202.
    • (1992) Lancet , vol.340 , Issue.8813 , pp. 199-202
    • Pilowsky, L.S.1    Costa, D.C.2    Ell, P.J.3    Murray, R.M.4    Verhoeff, N.P.5    Kerwin, R.W.6
  • 119
    • 0027337646 scopus 로고
    • Antipsychotic medication, D2 dopamine receptor blockade and clinical response: A 123I IBZM SPET (single photon emission tomography) study
    • Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med 23: 791-797.
    • (1993) Psychol Med , vol.23 , pp. 791-797
    • Pilowsky, L.S.1    Costa, D.C.2    Ell, P.J.3    Murray, R.M.4    Verhoeff, N.P.5    Kerwin, R.W.6
  • 120
    • 0344951296 scopus 로고    scopus 로고
    • D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine
    • Potkin SG, Basile VS, Jin Y., et al. (2003) D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 8 (1). 109-113.
    • (2003) Mol Psychiatry , vol.8 , Issue.1 , pp. 109-113
    • Potkin, S.G.1    Basile, V.S.2    Jin, Y.3
  • 121
    • 0019190758 scopus 로고
    • Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats
    • Pycock CJ, Kerwin RW, Carter CJ (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286 (5768). 74-76.
    • (1980) Nature , vol.286 , Issue.5768 , pp. 74-76
    • Pycock, C.J.1    Kerwin, R.W.2    Carter, C.J.3
  • 122
    • 0028172045 scopus 로고
    • Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine
    • Rao PA, Pickar D., Gejman PV, Ram A., Gershon ES and Gelernter J. (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 51 (11). 912-917.
    • (1994) Arch Gen Psychiatry , vol.51 , Issue.11 , pp. 912-917
    • Rao, P.A.1    Pickar, D.2    Gejman, P.V.3    Ram, A.4    Gershon, E.S.5    Gelernter, J.6
  • 123
    • 85047697539 scopus 로고    scopus 로고
    • Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients
    • Reynolds GP, Arranz B., Templeman LA, Fertuzinhos S., San L. (2006) Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163 (10). 1826-1829.
    • (2006) Am J Psychiatry , vol.163 , Issue.10 , pp. 1826-1829
    • Reynolds, G.P.1    Arranz, B.2    Templeman, L.A.3    Fertuzinhos, S.4    San, L.5
  • 124
    • 13244262700 scopus 로고    scopus 로고
    • Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
    • Reynolds GP, Yao Z., Zhang X., Sun J. and Zhang Z. (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15 (2). 143-151.
    • (2005) Eur Neuropsychopharmacol , vol.15 , Issue.2 , pp. 143-151
    • Reynolds, G.P.1    Yao, Z.2    Zhang, X.3    Sun, J.4    Zhang, Z.5
  • 125
    • 0030296697 scopus 로고    scopus 로고
    • Efficacy and side-effects of clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene
    • Rietschel M., Naber D., Oberlander H., et al. (1996) Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15 (5). 491-496.
    • (1996) Neuropsychopharmacology , vol.15 , Issue.5 , pp. 491-496
    • Rietschel, M.1    Naber, D.2    Oberlander, H.3
  • 126
    • 0030738648 scopus 로고    scopus 로고
    • Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor
    • Rietschel M., Naber D., Fimmers R., Moller HJ, Propping P., Nothen MM (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8 (8). 1999-2003.
    • (1997) Neuroreport , vol.8 , Issue.8 , pp. 1999-2003
    • Rietschel, M.1    Naber, D.2    Fimmers, R.3    Moller, H.J.4    Propping, P.5    Nothen, M.M.6
  • 127
    • 0036970070 scopus 로고    scopus 로고
    • Hippocampal volume in schizophrenia and its relationship with risperidone treatment: A stereological study
    • Savas HA, Unal B., Erbagci H., et al. (2002) Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. Neuropsychobiology 46 (2). 61-66.
    • (2002) Neuropsychobiology , vol.46 , Issue.2 , pp. 61-66
    • Savas, H.A.1    Unal, B.2    Erbagci, H.3
  • 128
    • 0343807441 scopus 로고    scopus 로고
    • Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene
    • Schafer M., Rujescu D., Giegling I., et al. (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158 (5). 802-804.
    • (2001) Am J Psychiatry , vol.158 , Issue.5 , pp. 802-804
    • Schafer, M.1    Rujescu, D.2    Giegling, I.3
  • 129
    • 0032739348 scopus 로고    scopus 로고
    • Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
    • Scharfetter J., Chaudhry HR, Hornik K., et al. (1999) Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 10 (1). 17-20.
    • (1999) Eur Neuropsychopharmacol , vol.10 , Issue.1 , pp. 17-20
    • Scharfetter, J.1    Chaudhry, H.R.2    Hornik, K.3
  • 130
    • 0034845769 scopus 로고    scopus 로고
    • The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients
    • Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS (2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25 (4). 468-475.
    • (2001) Neuropsychopharmacology , vol.25 , Issue.4 , pp. 468-475
    • Scheepers, F.E.1    Gispen-De Wied, C.C.2    Westenberg, H.G.3    Kahn, R.S.4
  • 132
    • 47549106824 scopus 로고    scopus 로고
    • Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area
    • Schwieler L., Linderholm KR, Nilsson-Todd LK, Erhardt S., Engberg G. (2008) Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83 (5-6). 170-175.
    • (2008) Life Sci , vol.83 , Issue.5-6 , pp. 170-175
    • Schwieler, L.1    Linderholm, K.R.2    Nilsson-Todd, L.K.3    Erhardt, S.4    Engberg, G.5
  • 133
    • 0010686493 scopus 로고
    • Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
    • Seeman P., Chau-Wong M., Tedesco J., Wong K. (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 72 (11). 4376-4380.
    • (1975) Proc Natl Acad Sci U S A , vol.72 , Issue.11 , pp. 4376-4380
    • Seeman, P.1    Chau-Wong, M.2    Tedesco, J.3    Wong, K.4
  • 134
    • 0029560535 scopus 로고
    • Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients
    • Shaikh S., Collier DA, Sham P., et al. (1995) Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 60 (6). 541-545.
    • (1995) Am J Med Genet , vol.60 , Issue.6 , pp. 541-545
    • Shaikh, S.1    Collier, D.A.2    Sham, P.3
  • 135
    • 0030005962 scopus 로고    scopus 로고
    • Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
    • Shaikh S., Collier DA, Sham PC, et al. (1996) Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 97 (6). 714-719.
    • (1996) Hum Genet , vol.97 , Issue.6 , pp. 714-719
    • Shaikh, S.1    Collier, D.A.2    Sham, P.C.3
  • 137
    • 33751331468 scopus 로고    scopus 로고
    • The relation between peripheral and central glutamate and glutamine in healthy male volunteers
    • Shulman Y., Grant S., Seres P., Hanstock C., Baker G., Tibbo P. (2006) The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci 31 (6). 406-410.
    • (2006) J Psychiatry Neurosci , vol.31 , Issue.6 , pp. 406-410
    • Shulman, Y.1    Grant, S.2    Seres, P.3    Hanstock, C.4    Baker, G.5    Tibbo, P.6
  • 138
    • 0029551796 scopus 로고
    • Association between clozapine response and allelic variation in the 5-HT2C receptor gene
    • Sodhi MS, Arranz MJ, Curtis D., et al. (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7 (1). 169-172.
    • (1995) Neuroreport , vol.7 , Issue.1 , pp. 169-172
    • Sodhi, M.S.1    Arranz, M.J.2    Curtis, D.3
  • 139
    • 54849230200 scopus 로고    scopus 로고
    • Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs-An Original Patient Data Meta-analysis of the SPECT and PET in Vivo Receptor Imaging Literature
    • Stone JM, Davis JM, Leucht S., Pilowsky LS (2008 a) Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs-An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature. Schizophr Bull.
    • (2008) Schizophr Bull
    • Stone, J.M.1    Davis, J.M.2    Leucht, S.3    Pilowsky, L.S.4
  • 140
    • 43149093378 scopus 로고    scopus 로고
    • Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: A [(123)I]CNS-1261 SPET study
    • Berl
    • Stone JM, Erlandsson K., Arstad E., et al. (2008 b) Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) 197 (3). 401-408.
    • (2008) Psychopharmacology , vol.197 , Issue.3 , pp. 401-408
    • Stone, J.M.1    Erlandsson, K.2    Arstad, E.3
  • 141
    • 34447547642 scopus 로고    scopus 로고
    • Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review
    • Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 21 (4). 440-452.
    • (2007) J Psychopharmacol , vol.21 , Issue.4 , pp. 440-452
    • Stone, J.M.1    Morrison, P.D.2    Pilowsky, L.S.3
  • 142
    • 0030903754 scopus 로고    scopus 로고
    • Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine
    • Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer HY (1997) Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res 69 (2-3). 113-121.
    • (1997) Psychiatry Res , vol.69 , Issue.2-3 , pp. 113-121
    • Sumiyoshi, T.1    Hasegawa, M.2    Jayathilake, K.3    Meltzer, H.Y.4
  • 143
    • 0034889660 scopus 로고    scopus 로고
    • 2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients
    • DOI 10.1097/00008571-200108000-00009
    • Suzuki A., Kondo T., Mihara K., et al. (2001) The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 11 (6). 545-550. (Pubitemid 32778231)
    • (2001) Pharmacogenetics , vol.11 , Issue.6 , pp. 545-550
    • Suzuki, A.1    Kondo, T.2    Mihara, K.3    Yasui-Furukori, N.4    Ishida, M.5    Furukori, H.6    Kaneko, S.7    Inoue, Y.8    Otani, K.9
  • 144
    • 0033623809 scopus 로고    scopus 로고
    • 2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients
    • Suzuki A., Mihara K., Kondo T., et al. (2000) The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10 (4). 335-341. (Pubitemid 30345181)
    • (2000) Pharmacogenetics , vol.10 , Issue.4 , pp. 335-341
    • Suzuki, A.1    Mihara, K.2    Kondo, T.3    Tanaka, O.4    Nagashima, U.5    Otani, K.6    Kaneko, S.7
  • 145
    • 0347363538 scopus 로고    scopus 로고
    • Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
    • Szekeres G., Keri S., Juhasz A., et al. (2004) Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124B (1). 1-5.
    • (2004) Am J Med Genet B Neuropsychiatr Genet , vol.124 , Issue.1 , pp. 1-5
    • Szekeres, G.1    Keri, S.2    Juhasz, A.3
  • 146
    • 26244458916 scopus 로고    scopus 로고
    • The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS)
    • Szulc A., Galinska B., Tarasow E., et al. (2005) The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 38 (5). 214-219.
    • (2005) Pharmacopsychiatry , vol.38 , Issue.5 , pp. 214-219
    • Szulc, A.1    Galinska, B.2    Tarasow, E.3
  • 147
    • 0028887499 scopus 로고
    • Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings
    • Szymanski S., Lieberman J., Pollack S., et al. (1995) Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. Biol Psychiatry 37 (1). 52-55.
    • (1995) Biol Psychiatry , vol.37 , Issue.1 , pp. 52-55
    • Szymanski, S.1    Lieberman, J.2    Pollack, S.3
  • 148
    • 0031776804 scopus 로고    scopus 로고
    • The role of negative symptoms and cognitive dysfunction in schizophrenia outcome
    • Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13 (Suppl 3). S21 - S26.
    • (1998) Int Clin Psychopharmacol , vol.13 , Issue.3
    • Tamminga, C.A.1    Buchanan, R.W.2    Gold, J.M.3
  • 149
    • 0025829372 scopus 로고
    • Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome
    • Tandon R., Mazzara C., DeQuardo J., et al. (1991) Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 29 (10). 953-964.
    • (1991) Biol Psychiatry , vol.29 , Issue.10 , pp. 953-964
    • Tandon, R.1    Mazzara, C.2    Dequardo, J.3
  • 150
    • 0034283750 scopus 로고    scopus 로고
    • Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response
    • Tsai SJ, Hong CJ, Yu YW, et al. (2000) Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 44 (3). 177-181.
    • (2000) Schizophr Res , vol.44 , Issue.3 , pp. 177-181
    • Tsai, S.J.1    Hong, C.J.2    Yu, Y.W.3
  • 151
    • 0035871218 scopus 로고    scopus 로고
    • Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response
    • Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ (2001) Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 49 (1-2). 53-58.
    • (2001) Schizophr Res , vol.49 , Issue.1-2 , pp. 53-58
    • Tsai, S.J.1    Wang, Y.C.2    Yu Younger, W.Y.3    Lin, C.H.4    Yang, K.H.5    Hong, C.J.6
  • 152
    • 33745703902 scopus 로고    scopus 로고
    • Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond
    • Tunbridge EM, Harrison PJ, Weinberger DR (2006) Catechol-o- methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60 (2). 141-151.
    • (2006) Biol Psychiatry , vol.60 , Issue.2 , pp. 141-151
    • Tunbridge, E.M.1    Harrison, P.J.2    Weinberger, D.R.3
  • 153
    • 9244243064 scopus 로고    scopus 로고
    • Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis
    • Tuominen HJ, Tiihonen J., Wahlbeck K. (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72 (2-3). 225-234.
    • (2005) Schizophr Res , vol.72 , Issue.2-3 , pp. 225-234
    • Tuominen, H.J.1    Tiihonen, J.2    Wahlbeck, K.3
  • 155
    • 0030606867 scopus 로고    scopus 로고
    • Predicting haloperidol treatment response in chronic schizophrenia
    • van Kammen DP, Kelley ME, Yao JK, et al. (1996) Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res 64 (1). 47-58.
    • (1996) Psychiatry Res , vol.64 , Issue.1 , pp. 47-58
    • Van Kammen, D.P.1    Kelley, M.E.2    Yao, J.K.3
  • 156
    • 7444232703 scopus 로고    scopus 로고
    • Catechol-Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications
    • Weickert TW, Goldberg TE, Mishara A., et al. (2004) Catechol- Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 56 (9). 677-682.
    • (2004) Biol Psychiatry , vol.56 , Issue.9 , pp. 677-682
    • Weickert, T.W.1    Goldberg, T.E.2    Mishara, A.3
  • 158
    • 33846624143 scopus 로고    scopus 로고
    • COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia
    • Woodward ND, Jayathilake K. and Meltzer HY (2007) COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 90 (1-3). 86-96.
    • (2007) Schizophr Res , vol.90 , Issue.1-3 , pp. 86-96
    • Woodward, N.D.1    Jayathilake, K.2    Meltzer, H.Y.3
  • 159
    • 13444301359 scopus 로고    scopus 로고
    • Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients
    • Wu S., Xing Q., Gao R., et al. (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376 (1). 1-4.
    • (2005) Neurosci Lett , vol.376 , Issue.1 , pp. 1-4
    • Wu, S.1    Xing, Q.2    Gao, R.3
  • 160
    • 33746466663 scopus 로고    scopus 로고
    • Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients
    • Wu SN, Gao R., Xing QH, et al. (2006) Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 27 (8). 966-970.
    • (2006) Acta Pharmacol Sin , vol.27 , Issue.8 , pp. 966-970
    • Wu, S.N.1    Gao, R.2    Xing, Q.H.3
  • 161
    • 34948887131 scopus 로고    scopus 로고
    • The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients
    • Xing Q., Qian X., Li H., et al. (2007) The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 10 (5). 631-637.
    • (2007) Int J Neuropsychopharmacol , vol.10 , Issue.5 , pp. 631-637
    • Xing, Q.1    Qian, X.2    Li, H.3
  • 162
    • 0036197150 scopus 로고    scopus 로고
    • Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients
    • Yazici K., Yazici AE, Taneli B. (2002) Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 26 (3). 579-584.
    • (2002) Prog Neuropsychopharmacol Biol Psychiatry , vol.26 , Issue.3 , pp. 579-584
    • Yazici, K.1    Yazici, A.E.2    Taneli, B.3
  • 163
    • 0025279268 scopus 로고
    • The incidence of abnormal dexamethasone suppression in schizophrenia: A review and a meta-analytic comparison with the incidence in normal controls
    • Yeragani VK (1990) The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry 35 (2). 128-132.
    • (1990) Can J Psychiatry , vol.35 , Issue.2 , pp. 128-132
    • Yeragani, V.K.1
  • 164
    • 0037347232 scopus 로고    scopus 로고
    • Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia
    • Yoshimura R., Ueda N., Shinkai K., Nakamura J. (2003) Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18 (2). 107-111.
    • (2003) Int Clin Psychopharmacol , vol.18 , Issue.2 , pp. 107-111
    • Yoshimura, R.1    Ueda, N.2    Shinkai, K.3    Nakamura, J.4
  • 166
    • 34948897970 scopus 로고    scopus 로고
    • Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients
    • Zai CC, Hwang RW, De Luca V., et al. (2007) Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 10 (5). 639-651.
    • (2007) Int J Neuropsychopharmacol , vol.10 , Issue.5 , pp. 639-651
    • Zai, C.C.1    Hwang, R.W.2    De Luca, V.3
  • 167
    • 12444307546 scopus 로고    scopus 로고
    • DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study
    • Zalsman G., Frisch A., Lev-Ran S., et al. (2003) DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 13 (3). 183-185.
    • (2003) Eur Neuropsychopharmacol , vol.13 , Issue.3 , pp. 183-185
    • Zalsman, G.1    Frisch, A.2    Lev-Ran, S.3
  • 168
    • 27744556147 scopus 로고    scopus 로고
    • Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine
    • Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD and Chen XG (2005) Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 115 (11). 1539-1547.
    • (2005) Int J Neurosci , vol.115 , Issue.11 , pp. 1539-1547
    • Zhao, A.L.1    Zhao, J.P.2    Zhang, Y.H.3    Xue, Z.M.4    Chen, J.D.5    Chen, X.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.